VeriStrat is a serum proteomic for patients with advanced NSCLC, which identifies patients likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).
According to the data, patients who tested VeriStrat Good showed considerably longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.
The VeriStrat test was applied to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients.
Of 46 patients, 37 were classified as either VeriStrat Good or VeriStrat Poor based on the VeriStrat algorithm developed for non-small cell lung cancer (NSCLC).